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1ABSTRACT
Inhibition of CK2 to overcome paclitaxel resistance in gastric cancer
Minkyu Jung
Department of Medicine,
The Graduate School, Yonsei University
(Directed by Professor Sun Young Rha)
Despite advances in treatment, gastric cancer (GC) remains among the most fatal 
malignancies. Paclitaxel has been used treatment for GC, however, it has limited 
clinical efficacy owing to drug resistance development. Casein kinase (CK) 2
activation has been implicated in the proliferation of various tumor types and 
resistance to chemotherapy. Herein, we investigated the mechanistic basis for the
association between CK2 activation and paclitaxel resistance. CK2 expression 
was evaluated by immunohistochemistry in formalin-fixed, paraffin-embedded 
tumor specimens from 59 advanced GC patients treated with paclitaxel as second-
line therapy. Patients with high CK2 expression (29/59, 39%) showed lower 
disease control rate (47.7 % vs. 72.3 %, p=0.017) and shorter progression-free 
2survival (2.8 vs. 4.8 months, p=0.009) than patients with low expression.
CK2 protein expression was associated with sensitivity to paclitaxel in 49 GC
cell lines. In SNU-1 line which showed paclitaxel resistance, high CK2
expression, and sensitivity to the CK2 inhibitor, 5-[(3-chlorophenyl)amino]-
benzo[c]-2,6 naphthyridine-8-carboxylic acid (CX-4945), combination therapy 
with CX-4945 and paclitaxel exerted synergistic antiproliferative effects and 
inhibited of down signaling of phosphatidylinositol 3-kinase/AKT signaling. 
These results demonstrate that CK2 activation is related to paclitaxel resistance
and that CX-4945 in combination with paclitaxel could be a treatment of choice
for paclitaxel resistance in GC
------------------------------------------------------------------------------------------------------------
Keywords: gastric cancer, paclitaxel, drug resistance, casein kinase II
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I. INTRODUCTION
Gastric cancer (GC) is major health problem worldwide, with high incidence and a poor 
prognosis.1 Surgical resection in combination with adjuvant chemotherapy is the only 
curative treatment strategy for localized GC.2,3 However, recurrence is common, and for 
advanced or metastatic GC, chemotherapy is the first treatment option. Although clinical 
trials have sought to improve survival rates in GC patients, the median overall survival
for metastatic disease is only about 1 year.4 Therefore, there is an urgent need for new 
strategies for improving treatment and survival.
Paclitaxel is effective for advanced GC treatment and has response rates in the range of 
15% to 28% when used as monotherapy.5-9 It is most commonly used as second-line 
therapy in GC and showed good toxicity profiles in stomach cancer.10 However, the 
4median duration of paclitaxel response in GC is only about 3 months, and eventually 
patients have paclitaxel resistance.11
The molecular mechanism underlying paclitaxel resistance is not well understood. 
Common mechanisms of drug resistance are overexpression of P-glycoprotein, and
protein kinase C-α (PKC-α), as well as mitogen-activated protein kinase and 
phosphatidylinositol-3-kinase (PI3K)/AKT signaling pathways.12-15 The PI3K/AKT
pathways is specially activated following paclitaxel treatment, whereas PI3K inhibition 
sensitized tumors to paclitaxel and included cell death via mitotic arrest.16-18
Casein kinase (CK) 2 recently has proposed anticancer drug target is a constitutively 
active serine/threonine kinase that has pro-survival/anti-apoptotic functions.19 Given that 
CK2 is the overexpressed in multiple cancers and is implicated in many non-oncogenic 
processes required to sustain the cancer phenotype, its selective inhibition is an attractive 
strategy for cancer treatment.19-21 CK2 has been shown to phosphorylate AKT1 at Ser129
to promote cell survival by generating a constitutively active form of the protein.22 It also
phosphorylates and stabilizes phosphatase and tensin homolog, thereby inhibiting its 
activity and inducing PI3K-mediated survival signaling and oncogensis.23 5-[(3-
chlorophenyl)amino]-benzo[c]-2,6 naphthyridine-8-carboxylic acid (CX-4945) is small 
5molecule, inhibitor of CK2 whose biological activity has been investigated in vitro and in 
vivo.24 Key attributes of CX-4945 include potent inhibition of CK2 enzymatic activity 
and a highly selective kinase profile.25 We speculated that paclitaxel resistance is 
associated CK2 activation and PI3K/AKT signaling, and that combining CK2 inhibition 
with paclitaxel chemotherapy can improve GC treatment efficacy.
To test this hypothesis, we investigated the association between CK2 expression and
paclitaxel resistance, and evaluated whether CX-4945 in combination with paclitaxel can
overcome paclitaxel resistance in GC.
6II. MATERIALS AND METHODS
1. Clinical specimens and chemotherapy protocol
We used paraffin blocks of surgical specimens or endoscopic biopsied specimens of 59 
advanced GC patients obtained before paclitaxel therapy at Yonsei University Health 
System (Seoul, Korea). All patients received paclitaxel (175mg/m2 on day 1 every 3 
weeks, or 70 - 80 mg/m2 on day 1, 8, and 15 every 4 weeks) as a second-line 
chemotherapeutic agent. Paclitaxel was given until disease progression or occurrence of 
intolerable toxicities. Tumor assessments were performed every two cycles, and disease 
response was categorized as complete response (CR), partial response (PR), stable 
disease (SD), and progressive disease (PD) according to the Response Evaluation 
Criteria in Solid Tumor (RECIST, v.1.1).26
2. Iimmunohistochemical analysis of CK2 and phosphorylated-AKT
CK2 and phosphorylated (p-) AKT expression was evaluated by
immunohistochemistry using anti-CK2 (Abcam, Cambridge, UK; 1:50) and anti- p-
AKT (Cell Signaling Technology, Danvers, MA, USA, 1:40) antibodies. Sections cut at 
7a thickness of 4 μm and mounted on slides were deparaffinized in xylene, rehydrated and 
treated with 2.5% H2O2 for 10 min to block endogenous peroxidase activity. Heat-
induced antigen retrieval was carried out for 2 min in 10 mmol/l citrate buffer (pH 7.0). 
After washing with phosphate-buffered saline (PBS), sections were incubated with 
primary antibody for 90 min at room temperature. After washing with PBS, sections were 
incubated at room temperature for 30 min with an anti-mouse secondary antibody 
followed by washing with PBS. Immunoreactivity was detected by incubation for 1 min
with 0.5% 3,3-diaminobenzidine solution. After washing with PBS, the sections were 
stained with Harris hematoxylin, and three areas per slide were analyzed to confirm tissue 
diagnosis. The numbers of tumor cells with membrane and cytoplasmic labeling of CK2
and cytoplasmic and nuclear labeling of p-AKT were counted. Scoring was performed by 
a pathologist blinded to patients’ clinical information. Protein expression was interpreted 
with weighted histoscore method.27 The intensity of protein expression was scored as 0
(negative), 1 (light brown), 2 (brown), and 3 (dark brown). The final score was calculated
as follows: - (0 × % of negative cells) + (1 × % of light brown cells) + (2 × % of brown 
cells) + (3 × % of dark brown cells). Patients were subdivided into following four groups 
based on the final score: 0 (negative), 1+ (final score; 1–100), 2+ (final score 101–200),
8and 3 + (final score 201–300). High CK2 and p-AKT expression was defined as a score 
≥ 1+.
3. Cell culture and reagents
A total of 49 GC cell lines were used in this study. The YCC series was established by 
the Yonsei Cancer Center (Cancer Metastasis Research Center, Seoul, Korea) from the 
ascites or peripheral blood of advanced GC patients. Other cell lines were obtained from
the Korean Cell Line Bank (Seoul National University, Seoul, Korea) and the American 
Type Culture Collection (American Type Culture Collection, Manassas, VA, USA).
Cells were maintained in Roswell Park Memorial Institute-1640 medium (Lonza, 
Walkersville, MD, USA) or Eagle’s minimal essential medium (Lonza, Walkersville, 
MD, USA) and supplemented with 10% fetal bovine serum (Omega Scientific, Tarzana, 
CA, USA), 100 U/ml penicillin, 100 mg/ml streptomycin, and 2 mmol/l glutamine in a
5% CO2-humidified atmosphere at 37°C. Cell lines were expanded and cryopreserved 
in liquid nitrogen in our laboratory.
CX-4945 was synthesized by and supplied without cost by Cylene Pharmaceuticals
(San Diego, CA, USA). Paclitaxel was purchased from Sigma-Aldrich (St. Louis, MO, 
9USA).
4. Cell growth inhibition assay
Cell proliferation was evaluated with 3-(4,5-dimethylthiazol-2yl)-2.5-
diphenyltetrazolimu bromide (MTT) assay. Cells were seeded at the density of 5 × 103
cells into a 96-well plate and incubated at 37°C for 24 h. Paclitaxel and CX-4945 were
serially diluted with medium and added to each well. After 72 h of incubation, 50 ml (2
mg/ml) of the MTT solution was added, and followed by incubation for an additional 4 h. 
After centrifugation at 400 × g for 10 min, the medium containing MTT was removed 
and the remaining MTT-formazan crystals were dissolved by adding 150 μl of
dimethylsulfoxide. After 10 min incubation with shaking, the absorbance at 570 nm was 
measured with a multi-well microplate read. Results are expressed as percentage cell 
survival, which was calculated which the following formula:  ¼ [(mean absorbance of 
test wells − standard absorbance) / (mean absorbance of control wells − standard 
absorbance)] × 100. Control wells were treated with the medium alone (without the drug).
At least 3 replicates were prepared for each treatment and the average of these data was
used for data analyses. Synergy was assessed using the New Bliss Independence Model.28
10
Combined percentage inhibition Yab, P was predicted using the complete addition of 
probability theory as Yab, P = Ya + Yb − YaYb (drug A at dose a inhibits Ya % of tumor 
growth and drug B at dose b inhibits Yb % of tumor growth). The observed combined 
percentage inhibition Yab, O was then compared as Yab, P, Yab, O > Yab, P, Yab, O = Yab, P, and 
Yab, O < Yab, P indicated that effects were synergistic, independent (additive), and 
antagonistic, respectively.
5. Detection of CK2 activity in cell lysates
GC lines were seeded in 6-well plates overnight, then collected at 80% confluence by 
scraping into ice-cold PBS. CK2 activity in cell lysates was determined using a CK2 
kinase assay kit (CycLex Co., Nagano, Japan) according to the manufacturer’s 
instructions.
6. CK2 RNA extraction
Total RNA was extracted with TRIzol reagent (Invitrogen, Carlsbad, CA, USA) 
according to the manufacturer’s instructions. First strand cDNA was synthesized from 2 
μg total cellular RNA with oligo (dT) using a cDNA synthesis kit (Fermentas, Hanover, 
11
MD, USA). Quantitative reverse transcription polymerase chain reaction (RT-PCR) was 
performed on a 7500 fast real-time PCR system (Applied Biosystems, Foster City, CA, 
USA) using Power SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, 
USA). The primers used were as follows: CK2a, 5ꞌ-
TGTCCGAGTTGCTTCCCGATACTT-3ꞌ and 5ꞌ-
TTGCCAGCATACAACCCAAACTCC-3ꞌ and glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), 5ꞌ-CCATGGAGAAGGCTG GGG-3ꞌ and 5ꞌ-
CAAAGTTGTCAT GGATGACC-3ꞌ. Relative copy number was determined using the 
comparative Ct method. GAPDH served as the internal control for normalization.
7. Cell cycle analysis
Cell cycling was evaluated by flow cytometry analysis of cells stained with propidium 
iodide (PI) (BD Biosciences, San Jose, CA, USA). SNU-1 cells were left untreated, or 
treated for 36 h with paclitaxel (0.1 or 1 μM), CX-4945 (5 or 1 μM ) typsinized, fixed
overnight with 70% ethanol at −20°C and incubated for 30 min in the dark at room 
temperature with 200 μl PI solution. After washing with PBS, cells were resuspended in 
500 μl PBS analyzed on a FACS Calibur system (BD Biosciences, San Jose, CA, USA).
12
8. Western blot analysis 
SNU-1 cells were washed twice in PBS, lysed in ice-cold buffer composed of 1% 
Nonidet P-40, 10% (v/v) glycerol, 20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 2.5 mM 
EDTA, 100 μM Na3VO4, 1% aprotinin, 1% leupeptin, and 1 mM perfluoro-1-
butanesulfonyl fluoride for 30 min at 4°C and centrifuged 13,000 rpm for 20 min at 4°C. 
The supernatant was collected and total protein concentration was quantified by the 
Bradford assay and stored at −70°C until use. For western blotting, proteins were mixed 
with 5 × sample buffer and boiled at 95°C for 5 min, then resolved by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis using 7.5% or 10% polyacrylamide gels, 
followed by transfer to a polyvinylidene difluoride membrane (GE Healthcare, 
Piscataway, NJ, USA) by electroblotting. The membrane was blocked with 5% skim 
milk for 1 h at room temperature and incubated overnight with primary antibodies 
against the following proteins: p-CK2 (pS/pTDXE, #8738), AKT (Ser473, #9272), p-
AKT (Ser473, #4058), mammalian target of rapamycin (mTOR) (7C10, #2983), p-
mTOR (Ser2448, #2971), p70S6K (#9202), p-p70S6K (Thr387, #9234), and cleaved 
PARP1 (Asp214, #9541) (all from Cell Signaling Technology); anti-p-AKT (Ser129, 
ab133458, Abcam, Cambridge, UK); and CK2 (1AD9, sc-12738, Santa Cruz 
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Biotechnology, Santa Cruz, CA, USA). Horseradish peroxidase-conjugated anti-mouse 
and -rabbit IgG (Santa Cruz Biotechnology) were used as secondary antibodies. The 
membrane was developed by enhanced chemiluminescence (GE Healthcare, Piscataway, 
NJ, USA). Anti-alpha tubulin antibody (#T6199; Sigma-Aldrich) was used as a loading 
control. Protein band signal intensities were quantitated with ImageJ software (National 
Institutes of Health, Bethesda, MD, USA).
9. Statistical analysis
Clinical characteristics and treatment outcomes of patients were compared according 
to CK2 expression with the χ2 test and Fisher’s exact test. Survival estimates were 
calculated using the Kaplan-Meier method. Progression-fee survival (PFS) was calculated 
from the date chemotherapy was started to the earliest date of disease progression or 
death from any other cause. And overall survival (OS) was defined as the time from the 
start of paclitaxel treatment to death from any cause. Differences in PFS and OS
according to CK2 and p-AKT expression were compared with the log-rank test.
Significant effects between treatment groups or between treatment and control groups
were evaluated with using the Mann-Whitney U test. Data were analyzed SPSS, v 23.0 
14
(SPSS Inc., Chicago, IL, USA) and plots and curves were generated with Prism v.5 
software (GraphPad Inc., San Diego, CA, USA). 
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III. RESULTS
1. Patient characteristics
A total of 59 patients for whom tumor tissue specimens were available for CK2 and p-
AKT expression analysis were included in this study. The median age was 59 years 
(range, 53-68 years), and 62.7% was male. About 60% patients were underwent 
gastrectomy before paclitaxel treatment (Table 1), eight (13.6%) were positive human 
epidermal receptor 2 (HER2).
16
Table 1. Patients’ clinicopathologic characteristics
Characteristics Number %
Age
Median 59
IQR 53-68
Sex
Male 37 62.7
Female 22 37.3
WHO classification
Adenocarcinoma well differentiated 6 10.2
Adenocarcinoma moderately differentiated 15 25.4
Adenocarcinoma poorly differentiated 26 44.1
Signet ring cell 9 15.5
Others 3 5.2
Prior gastrectomy
Yes 36 61
No 23 39
HER2 status
Positive 8 13.6
Negative 39 66.1
Unknown 12 20.3
Disease
Measurable 30 62.7
Non-measurable 22 37.3
Metastatic location
Distant Lymph node 16 27.1
Liver 13 22
Peritoneum 37 62.7
Lung 3 5.1
Bone 2 3.4
HER2, human epidermal receptor 2; IQR, interquartile range; WHO, World Health 
Organization
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2. Expression of CK2 and p-AKT in GC patients
Median CK2 and p-AKT immunoreactivity scores were 50 (range, 0-210) and 110 
(range, 0-270), respectively. At a cutoff score of 1+, CK2 and p-AKT expression was 
high in 23 (40%) and p-AKT in 40 (67.8%) of the 59 patients, respectively (Figure 1).
18
Figure 1. CK2 and p-AKT protein expression in tumor tissue from gastric cancer
patients. (A) CK2 and (B) p-AKT immunoreactivity was graded as a) negative, b) 
weak (light brown), c) moderate (brown), or d) strong (dark brown). Original
magnification: 200x, Scale bar: 50μm.
3. Association between CK2 and p-AKT expression and paclitaxel response
Response to paclitaxel was evaluated 56 of 59 patients. Two patients could not undergo 
a second cycle of chemotherapy due to decreased performance status, and one patient
refused chemotherapy after the first treatment cycle. The overall response rate (ORR)
was 10.2% and the disease control rate (DCR = CR + PR + SD) was 62.7%. There was 
no association between ORR or DCR and p-AKT expression. However, patients with 
19
high CK2 levels had lower DCR (47.8% vs. 72.3%, p = 0.017) (Table 2).
Table 2. Response according to expression of CK2 and p-AKT
All
(%)
CK2 p-AKT
Positive Negative p-
value
Positive Negative p-
value(n=23) (n=36) (n=40) (n=19)
CR 0 0 0 0.004 0 0 0.295
PR 6 (10.2) 4 (17.4) 2 (5.6) 2 (5) 4 (21.1)
SD
31 
(52.5)
7 (30.4)
24 
(66.7)
22 (55) 9 (47.4)
PD
19 
(32.2)
12 
(52.2)
7 (19.4) 14 (35) 5 (26.3)
NE  3 (5.1) 0 3 (8.3) 2 (5) 1 (5.3)
ORR 6 (10.2) 4 (17.4) 2 (5.6) 0.181 2 (5) 4 (21.1) 0.077
DCR
37 
(62.7)
10 
(47.8)
26 
(72.3)
0.017 24 (60)
13 
(68.5)
0.503
CR, complete response; DCR, disease control rate; NE, not evaluable or not assessed; 
ORR, overall response rate; p-AKT, phosphorylated AKT; PD, progressed disease; PR, 
partial response; SD, stable disease
4. Association between CK2 and p-AKT expression and patients survival following
paclitaxel therapy
In all patients, the median PFS and OS were 3.5 months [95% confidential interval 
(CI); 2.7 - 4.3 months] and 8.9 months (95% CI; 6.3 - 10.8 months), respectively. There 
was no difference in PFS according to age and sex, and no difference in PFS and OS 
according to p-AKT expression. However, PFS was longer in patients with low as 
20
compared with high CK2 expression (median PFS, 4.1 vs. 2.8 months, p = 0.009). OS
was not associated with CK2 expression (Figure 2). 
Figure 2. Kaplan-Meier survival curve according to CK2 expression. (A) PFS in 59 
21
patients; the median values for patients with low and high CK2 expression were 4.1 
months versus 2.8 months (p=0.009). (B) There was no difference of OS according to 
CK2 level.
5. Paclitaxel sensitivity in 49 GC cell lines
Since CK2 protein expression was associated with paclitaxel resistance in tumor tissue 
of gastric cancer patients, we investigated the association between paclitaxel sensitivity 
and CK2 expression in 49 gastric cancer cell lines. The antiproliferative effect of 
paclitaxel was evaluated with the MTT assay. The YCC-30 cell line was the most 
sensitive to paclitaxel treatment with half-maximal inhibitory concentration (IC50) of 
0.0003 μM; in contrast, YCC-25, YCC-28, and YCC-33 cells were highly resistant to the 
effects of paclitaxel IC50 ≥10 μM. The cut-off level of paclitaxel sensitivity/resistance is
0.1 μM Catalogue of Somatic Mutations in Cancer (http://cancer.snager.ac.uk/cosmic).
According to this value, 18 cell lines (36.7%) were resistant to paclitaxel (Figure 3).
22
Figure 3. Antiproliferative effect of paclitaxel against 49 gastric cell lines. GC cell lines (n = 49) were treated with increasing doses of paclitaxel 
and IC50 was determined with the MTT assay. The most sensitive cell line was YCC-30 (IC50 = 0.0003 μM), whereas SNU-1 cells showed the 
highest resistance (IC50 = 7.2 μM). *Cutoff level for resistance to paclitaxel defined according to the Catalogue of Somatic Mutations in Cancer 
database.
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6. Association between CK2 expression and paclitaxel sensitivity
We evaluated CK2 mRNA and protein expression, and CK2 activity in 49 GC cell lines. 
Paclitaxel-resistant cell lines had higher CK2 protein expression than those that were 
sensitivity the the drug (p=0.041, Figure 3A). However, neither CK2 mRNA nor activity 
was correlated with paclitaxel sensitivity (Figure 4B and 4C). p-AKT expression was not 
associated with paclitaxel resistance (Figure 4D). 
24
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Figure 4. Association between CK2 expression and paclitaxel sensitivity. (A) CK2 
protein levels in 49 gastric cell lines were evaluated by western blotting and compared 
between paclitaxel-sensitive and -resistant cells. (B) CK2 mRNA expression was 
assessed by quantitative reverse transcription PCR and compared between paclitaxel-
sensitive and -resistant lines. (C) CK2 kinase activity was evaluated by the CK2 kinase 
assay and compared between paclitaxel-sensitive and -resistant lines. (D) p-AKT 
expression was assessed by western blotting and compared between paclitaxel-sensitive 
and -resistant cell lines. The mRNA and protein levels were normalized to those of Jurkat 
cells. *p < 0.05; ns, not significant.
7. Association between CK2 expression and CX-4945 sensitivity in GC cells
We treated the GC cell lines with CX-4945 and found that the IC50 ranged from 2.7 to 
>100 μM. The cell lines were divided into CX-4945-sensitive and -resistant groups, with 
a cut-off CX-4945 IC50 of 10 μM. According to this value, 20 cell lines were sensitive to
26
CX-4945. High CK2 protein expression was correlated with CX-4945 sensitivity (p =
0.058); however, there was no association between CK2 mRNA or activity and CX-
4945 sensitivity (Figure 5).
27
Figure 5. Association between CK2 expression and CX-4945 sensitivity. (A) CK2 protein 
levels in 49 gastric cell lines were evaluated by western blotting and compared between 
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CX-4945-sensitive and -resistant cells. (B) CK2 mRNA expression was assessed by 
quantitative reverse transcription PCR and compared between CX-4945-sensitive and -
resistant lines. (C) CK2 kinase activity was evaluated by the CK2 kinase assay and 
compared between CX-4945-sensitive and -resistant lines. The mRNA and protein levels 
were normalized to those of Jurkat cells
8. Synergistic effect of paclitaxel and CX-4945 on proliferation of paclitaxel 
resistant SNU-1 cells
The above results indicated that CK2 expression was associated with paclitaxel 
resistance and that CX-4945 was effective in cell lines with CK2 protein expression. 
We therefore, speculated that combined treatment of paclitaxel and CX-4945 could 
overcome paclitaxel resistance. We tested our hypothesis by treating paclitaxel-resistant 
(IC50 = 1.122 μM, Figure 3), CX-4945-sensitive (IC50 = 7.2 μM) SNU-1 cells with 
paclitaxel (0.1 or 1 μM monotherapy), CX-4945 (5 or 10 μM monotherapy), or both 
(0.1 μM paclitaxel, and 5 or 10 μM CX-4945). The combination of both drug had
synergistic inhibitory effect on cell proliferation relative to CX-4945 or paclitaxel 
monotherapy according to New Bliss Independence Model (Yab, O = 0.767 > Yab,
P=0.478) (Figure 6)
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Figure 6. Synergistic antiproliferative effects of paclitaxel and CX-4945 in SNU-1 cells. 
The additivity line is equivalent to the theoretical combined antiproliferative effects of 
drugs A and B [%A + %B (100 −%A/100] in which %A and %B are the percentages of 
cells killed by drugs A and B, respectively, at a given concentration. *28.9%.
We investigated whether paclitaxel, CX-4945, or their combination inhibited SNU-1 
cell-cycle progression of SNU-1 by flow cytometry. The proportion of cells in G2/M 
phase was increased by concomitant treatment with both drugs (Figure 7). Notably, G2/M 
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arrest was markedly increased in these cells treated with paclitaxel combined with CX-
4945. 
Figure 7. Cell cycle analysis of paclitaxel and CX-4945 in SNU-1 cells. SNU-1 cells 
were treated with CX-4945 (5 or 10 μM), paclitaxel (0.1 or 1 μM), and paclitaxel (0.1 
μM) combined with CX-4949 (5 or 10 μM) for 36 h, and cell cycle distribution was 
analyzed by flow cytometry. The fraction of cells in sub-G1, G0/G1, S, and G2/M 
phases of the cell cycle is shown. Combined treatment of paclitaxel and CX-4945 
induced G2/M arrest
9. Effects of paclitaxel combined with CX-4945 on CK2 expression, 
PI3K/AKT signaling, and apoptosis in SNU-1 cells
The effects of combined paclitaxel and CX-4945 treatment on CK2 expression, 
PI3K/AKT signaling, and apoptosis were analyzed by western blotting analysis in 
SNU-1 cells. CX-4945 decreased phosphorylation of CK2, AKT and downstream 
signaling protein p70S6K, while paclitaxel has opposite effect. CX-4945 combined
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with paclitaxel decreased p-CK2, p-AKT, p- p70S6K expression. The effect of CX-4945 
on apoptosis was also investigated by evaluating cleaved poly (ADP-ribose) polymerase
(PARP)-1 protein expression. CX-4945 and paclitaxel monotherapy induced cleaved 
PARP-1 expression; this effect was potentiated by combination treatment with both drugs
(Figure 8).
Figure 8. Effect of CX-4945 combined with paclitaxel on the CK2 expression, 
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PI3K/AKT signaling, and apoptosis in SNU-1 cells. SNU-1 cells were treated with 
vehicle, CX-4945 (5 or 10 μM), paclitaxel (0.1 or 1 μM), and paclitaxel (0.1 μM) 
combined with CX-4949 (5 or 10 μM) for 48h. Western blotting was conducted to assess 
AKT signaling 
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IV. DISCUSSION
In this study, we examined the relationship between CK2 expression and paclitaxel 
resistance in GC. CK2 is a ubiquitous serine/threonine kinase that regulates a variety of 
cellular processes including cell cycling, proliferation, and apoptosis.29 CK2
overexpression is correlated with tumorigenesis in various types of cancer as well as 
with the degree of tumor invasion; more over, patients with elevated levels of CK2 had 
lower overall survival in surgically resected GC.21,30,31 Interestingly, CK2 was shown to 
exert anti-apoptotic effects via upregulation of AKT.22 Given that PI3K/AKT activation 
is associated with paclitaxel resistance, we speculated that CK2 is also related to 
paclitaxel resistance via the PI3K/AKT pathway in GC. 16,17,32
To test our hypothesis, we investigated CK2 expression in the tumor tissue of GC
patients treated with paclitaxel as second-line chemotherapy. As predicted, CK2 
overexpression was correlated with paclitaxel resistance. Patients with higher CK2
expression levels had significantly shorter survival and lower DCR from paclitaxel 
therapy as compared to those with low CK2 expression. The association of between
CK2 expression and paclitaxel resistance was confirmed in vitro using GC cell lines. 
CX-4945 is a potent and selective small-molecule inhibitor of CK2 that is active against 
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a broad range of malignancies, including breast, colon, pancreas, prostate, ovarian, and 
lung cancer.33 The efficacy of CX-4945 against GC has been not previously reported. 
We identified 20 GC cell lines among 49 that were CX-4945 sensitive cell lines, with a 
CX-4945 IC50 cut-off level of 10 μM. Cell lines with high CK2 protein expression 
trended to be sensitive to CX-4945. Combination treatment of SNU-1 which
overexpress CK2 protein and show paclitaxel resistance, and CX-4945 sensitivity with 
paclitaxel and CX-4945 had a synergistic effect on proliferation relative to cell treated 
with either drug alone. Combination treatment and CX-4945 monotherapy also 
decreased the phosphorylation of of CK2, AKT, and the downstream factor p70S6K, 
whereas paclitaxel monotherapy had the opposite effect. This suggests that PI3K/AKT 
activation by paclitaxel may contribute to paclitaxel resistance. Indeed, PI3K/AKT 
signaling was suppressed by CK2 inhibition, leading to cell cycle arrest and apoptosis. 
Given our observation that CK2 activation is related with paclitaxel resistance, CX-
4945 in combination with paclitaxel could be a treatment of choice in paclitaxel-
resistant GC. However, the inhibition of CK2 to overcome paclitaxel resistance requires 
confirmation xenograft model before clinical trials are initiated. In addition, paclitaxel
sensitivity must be evaluated, according to the different molecular subtypes of GC 
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which have been shown to be associated with distinct clinical outcomes34,35 Two genes,
involved in tubulin processing-tubulin gamma complex-associated protein 4 and N-
acetyltransferase 10- were related to poor prognosis in the Stem-A subtype  of ovarian 
cancer, which exhibits elevated microtubule activity and is sensitive to several 
microtubule polymerization-inhibiting drugs; such as vincristine and vinorelbine.36 It is 
possible that GC subtype also have variable sensitivity to microtubule inhibitors.
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V. CONCLUSION
The results presented here suggest that high CK2 expression is negative predictive 
marker for paclitaxel response in GC. Paclitaxel resistance was related to CK2
expression through the PI3K/AKT signaling pathway. Our findings suggested that CK2 
inhibition with CX-4945 which induces G2/M cell cycle arrest and increases apoptosis 
by suppressing PI3K/AKT signaling in combination with paclitaxel can be effective 
against paclitaxel resistant GC.
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ABSTRACT (IN KOREAN)
위암에서 paclitaxel 저항 극복 방법으로서 CK2의 억제 효과
<지도교수 라선영>
연세대학교 대학원 의학과
정민규
진행성 위암은 치료 발전에도 불구하고, 여전히 예후가 않좋은 암중에
하나이다. 파클리탁셀은 위암의 주된 항암제 중에 하나이나, 
저항기전으로 인해 그 효과는 제한적이다. 최근, Casein kinase 2 (CK2)의
활성화는 다양한 암종에서 종양의 증식과 연관되고, 항암제 저항성과
관계되는 연구가 보고되고 있다. 따라서, 본 연구는 위암에서, 
파클리탁셀의 저항성과 CK2 활성화에 대해 조사하고자 하였다. 2차
약제로 파클리탁셀로 치료 받은 59명의 진행성 위암환자를 대상으로, 
치료 전 종양조직을 이용하여 면역 화학 조직 염색법으로 CK2 발현을
조사하였다. CK2가 과발현 된 환자는 (29/59, 39%), CK2가 발현되지
않은 환자에 비해 질병 조절율이 통계학적으로 낮았으며 (47.7 % vs. 
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72.3 %, p=0.017), 무진행 생존율도 짧았다 (2.8 months vs. 4.8 months, 
p=0.009).
49 개의 위암 세포주를 이용하여 파클리탁셀 및 CK2 억제제인
CX-4945 에 대한 항증식효과를 조사한 결과 CK2 단백질의 과발현과
파클리탁셀의 저항성과 상관관계가 있었다. 49개의 위암세포주 중에
파클리탁셀에 저항성이 있으며, CK2 단백질이 과발현을 보이며, CX-
4945 에 민감한 세포 주인 SNU-1 세포주를 선택하여, 파클리탁셀과
CX-4945 와 병합 치료하였을 경우 항종양 상승효과가 있었으며, 
PI3K/AKT 경로를 통해 억제됨을 확인 하였다.
결론적으로, CK2 과발현은 위암에서 파클리탁셀의 저항성과
관련이 있었으며, paclitaxel 과 CK2 억제제인 CX-4945 를 병합치료는
파클리탁셀의 저항성을 극복하는 치료 방법이 될 수 있을 것이다.   
------------------------------------------------------------------------------------------------------------
핵심되는 말: 위암, 파클리탁셀, 약물 저항성, casein kinase II
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